Patents by Inventor Axel Tome
Axel Tome has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230310610Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt therof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.Type: ApplicationFiled: February 27, 2023Publication date: October 5, 2023Inventors: Jamey Weichert, Anatoly Pinchuk, Wolfgang Axel Tome
-
Patent number: 11623007Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt therof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.Type: GrantFiled: September 25, 2020Date of Patent: April 11, 2023Assignee: Wisconsin Alumni Research FoundationInventors: Jamey Weichert, Anatoly Pinchuk, Wolfgang Axel Tome
-
Publication number: 20210008203Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt therof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.Type: ApplicationFiled: September 25, 2020Publication date: January 14, 2021Inventors: Jamey Weichert, Anatoly Pinchuk, Wolfgang Axel Tome
-
Patent number: 10813998Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt thereof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.Type: GrantFiled: February 26, 2019Date of Patent: October 27, 2020Assignee: Wisconsin Alumni Research FoundationInventors: Jamey Weichert, Anatoly Pinchuk, Wolfgang Axel Tome
-
Publication number: 20190184014Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt thereof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.Type: ApplicationFiled: February 26, 2019Publication date: June 20, 2019Inventors: Jamey Weichert, Anatoly Pinchuk, Wolfgang Axel Tome
-
Patent number: 10265398Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt thereof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.Type: GrantFiled: November 4, 2016Date of Patent: April 23, 2019Assignee: Wisconsin Alumni Research FoundationInventors: Jamey Weichert, Anatoly Pinchuk, Wolfgang Axel Tomé
-
Publication number: 20170128572Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula: or a salt thereof. R1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.Type: ApplicationFiled: November 4, 2016Publication date: May 11, 2017Inventors: Jamey Weichert, Anatoly Pinchuk, Wolfgang Axel Tomé
-
Patent number: 9140306Abstract: The invention relates to a rotational movement damper (1) comprising an outer sleeve (2) and an axle which fits in the outer sleeve (2) and mounted to rotate in the outer sleeve. The axle comprises at least two discoidal flanges (7, 8, 17, 18) with flat flange surfaces (9, 10) and the same diameter, fitting in annular channels (12, 13, 14, 15) in the outer sleeve (2) such that the flanges contact with the planar flange surfaces (9, 10) thereof against the equally planar area on the counter surfaces of the annular channels (12, 13, 14, 15) unaffected by temperature variations and, on counter-rotation of the outer sleeve (2) and axle (3) act as a slipper clutch.Type: GrantFiled: September 21, 2009Date of Patent: September 22, 2015Assignee: Ejot GmbH & Co. KGInventors: Rolf Kuenkel, Walter Kornsteiner, Reinhold Lenherr, Axel Tome
-
Patent number: 8897857Abstract: A method of producing a patient image indicating proton stopping power of the tissue may employ photon attenuation information converted to proton stopping power. The conversion uses different conversion functions for particular tissue types to account for a strong atomic number dependency in the conversion process. Megavoltage x-rays may be used for improved accuracy.Type: GrantFiled: October 31, 2011Date of Patent: November 25, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Wolfgang Axel Tomé, Dongxu Wang, Thomas R. Mackie
-
Patent number: 8545152Abstract: The invention relates to a screw which can be screwed into a component and which will resist further screwing into an internal thread within said component once a maximum torque has been reached. For this purpose, a screw body having an external thread is combined with a screw drive element which projects into a bore within said screw body and, within said bore, is connected to the screw body via static friction. At least part of this combination is made of a plastic material, with the static friction having the effect of a slipping clutch when a maximum torque acts on the screw drive element. The screw drive element is connected to the screw body via a ratchet in such a way that when the screw body is unscrewed from the internal thread within said component, turning said screw drive element will cause the ratchet to engage, thereby entraining the screw body.Type: GrantFiled: September 22, 2009Date of Patent: October 1, 2013Assignee: Ejot GmbH & Co., KGInventors: Rolf Kuenkel, Walter Kornsteiner, Reinhold Lenherr, Axel Tome
-
Patent number: 8526692Abstract: Deformation maps (e.g. deformation vector fields) used for correcting image-type data used in the treatment of patients in radiotherapy may be processed to eliminate inverse inconsistency and transitivity type errors which produce different results depending on the order or path of the calculation of deformation. The correction permits registration of a treatment plan with the changing patient image and accumulation of dose to a common reference frame without transformation dependent artifacts.Type: GrantFiled: June 30, 2011Date of Patent: September 3, 2013Assignee: Wisconsin Alumni Research FoundationInventors: Wolfgang Axel Tomé, Edward Thomas Bender, Nicholas Gordon Lance Hardcastle
-
Publication number: 20130108014Abstract: A method of producing a patient image indicating proton stopping power of the tissue may employ photon attenuation information converted to proton stopping power. The conversion uses different conversion functions for particular tissue types to account for a strong atomic number dependency in the conversion process. Megavoltage x-rays may be used for improved accuracy.Type: ApplicationFiled: October 31, 2011Publication date: May 2, 2013Inventors: Wolfgang Axel Tomé, Dongxu Wang, Thomas R. Mackie
-
Publication number: 20130004034Abstract: Deformation maps (e.g. deformation vector fields) used for correcting image-type data used in the treatment of patients in radiotherapy may be processed to eliminate inverse inconsistency and transitivity type errors which produce different results depending on the order or path of the calculation of deformation. The correction permits registration of a treatment plan with the changing patient image and accumulation of dose to a common reference frame without transformation dependent artifacts.Type: ApplicationFiled: June 30, 2011Publication date: January 3, 2013Inventors: Wolfgang Axel Tomé, Edward Thomas Bender, Nicholas Gordon Lance Hardcastle
-
Publication number: 20110236153Abstract: The invention relates to a screw which can be screwed into a component and which will resist further screwing into an internal thread within said component once a maximum torque has been reached. For this purpose, a screw body having an external thread is combined with a screw drive element which projects into a bore within said screw body and, within said bore, is connected to the screw body via static friction. At least part of this combination is made of a plastic material, with the static friction having the effect of a slipping clutch when a maximum torque acts on the screw drive element. The screw drive element is connected to the screw body via a ratchet in such a way that when the screw body is unscrewed from the internal thread within said component, turning said screw drive element will cause the ratchet to engage, thereby entraining the screw body.Type: ApplicationFiled: September 22, 2009Publication date: September 29, 2011Applicant: EJOT GMBH & CO. KGInventors: Rolf Kuenkel, Walter Kornsteiner, Reinhold Lenherr, Axel Tome
-
Patent number: 7551717Abstract: A virtual 4D treatment suite includes a dose calculation module, a gating module, and a dose rate adjustment module. The 4D treatment suite may be used to virtually analyze the impact the motion of a target tissue has on therapy for a particular patient and a proposed treatment plan. For example, for a proposed treatment plan, the dose calculation module may calculate a dose that would be received by a target tissue and an associated dose temporal variation based on an identified movement of the target tissue relative to at least a portion of a treatment field. Based on the calculated expected therapy dose and dose temporal variation, the gating module may determine whether to implement a gating technique for the proposed treatment plan and/or the dose rate adjustment module may determine whether to adjust the dose rate of the proposed treatment plan.Type: GrantFiled: August 21, 2007Date of Patent: June 23, 2009Assignees: Wisconsin Alumni Research Foundation, Koninklijke Philips Electronics NVInventors: Wolfgang Axel Tomé, Eric Drew Ehler
-
Publication number: 20090052623Abstract: A virtual 4D treatment suite includes a dose calculation module, a gating module, and a dose rate adjustment module. The 4D treatment suite may be used to virtually analyze the impact the motion of a target tissue has on therapy for a particular patient and a proposed treatment plan. For example, for a proposed treatment plan, the dose calculation module may calculate a dose that would be received by a target tissue and an associated dose temporal variation based on an identified movement of the target tissue relative to at least a portion of a treatment field. Based on the calculated expected therapy dose and dose temporal variation, the gating module may determine whether to implement a gating technique for the proposed treatment plan and/or the dose rate adjustment module may determine whether to adjust the dose rate of the proposed treatment plan.Type: ApplicationFiled: August 21, 2007Publication date: February 26, 2009Applicant: Wisconsin Alumni Research FoundationInventors: Wolfgang Axel Tome, Eric Drew Ehler